Glaxosmithkline Share News (GSK)
GSK Share
GSK Share
GSK Share
GSK Share
GSK
GSK Share
GSK Level 2
GSK Live
GSK Broker
GSK Directors
GSK Financial
GSK
GSK Short
GSK
Last checked at -
* Standalone strategy hinges on new drugs delivering * AstraZeneca has had more than fair share of flops in past * Experiences with Exanta, other failures haunt company By Ben Hirschler LONDON, May 20 (Reuters) - AstraZeneca's confidence in its promising new drugs may have
Read more* Money would fund GAVI's programmes from 2016 to 2020 * GAVI works with drugmakers to cut vaccine costs for poor * 1.5 mln children a year die of vaccine-preventable disease By Kate Kelland LONDON, May 20 (Reuters) - The GAVI global vaccines alliance issued a plea on Tues
Read moreMay 19 (Reuters) - GlaxoSmithKline and Danish biotech company Genmab said disappointing results from a study on treating relapsed lymphoma with their ofatumumab drug meant it was unlikely they would seek its regulatory approval. A head-to-head phase III study of ofatumumab and another drug
Read more
The pharmaceutical sector was dragged into the red on Monday as shares in AstraZeneca were hit by the news that the board has rejected another offer from US rival Pfizer. AstraZeneca was trading 11.5% lower at 4,270p after turning down a sweetened 5,500p-a-share bid from Pfizer. The new offer, wh
Read moreSHANGHAI, May 19 (Reuters) - A Chinese state-run newspaper has accused British drugmaker GlaxoSmithKline Plc of evading at least 100 million yuan ($16.04 million) in taxes, adding to pressure on the firm which is already struggling with graft charges against executives. Chinese police on We
Read more(Repeats from Sunday, no changes to text) By Adam Jourdan and John Ruwitch SHANGHAI, May 18 (Reuters) - Chinese corruption charges against executives of British drugmaker GlaxoSmithKline Plc (GSK) could be just the start of the pharmaceutical industry's problems in its biggest emergin
Read moreBy Adam Jourdan and John Ruwitch SHANGHAI, May 18 (Reuters) - Chinese corruption charges against executives of British drugmaker GlaxoSmithKline Plc (GSK) could be just the start of the pharmaceutical industry's problems in its biggest emerging drugs market, according to industry sources in
Read more
LONDON (Alliance News) - A connected person of GlaxoSmithKline PLC Chief Executive Andrew Witty Friday sold 726 shares at 1,638.6078 pence before repurchasing 720 shares at 1,638.9148p and transferring them into an individual savings account, the company said. Glaxo shares Friday closed at
Read more(Adds quotes, details on case) By Adam Jourdan SHANGHAI, May 16 (Reuters) - Corruption charges against GlaxoSmithKline Plc executives in China are a warning to other foreign firms and could do irreparable damage to the British drugmaker's Chinese operations, the official Xinhua news a
Read moreSHANGHAI, May 16 (Reuters) - Corruption charges against British drugmaker GlaxoSmithKline Plc in China are a "warning" to other foreign firms operating in the country that unethical behaviour will be punished, according to a commentary from the official Xinhua news agency on Friday. Chinese
Read more(Adds GSK declining to comment, UK Serious Fraud Office) By Adam Jourdan and Kazunori Takada SHANGHAI, May 15 (Reuters) - GlaxoSmithKline Plc executive Mark Reilly had little inkling he would be charged with leading a network of corruption in China's pharmaceutical industry, two sour
Read moreBy Adam Jourdan and Kazunori Takada SHANGHAI, May 15 (Reuters) - GlaxoSmithKline Plc executive Mark Reilly had little inkling he would be charged with leading a network of corruption in China's pharmaceutical industry, two sources with ties to the businessman and knowledge of the investiga
Read moreLONDON (Alliance News) - The following UK shares received analyst recommendations Thursday morning:
----------
FTSE 100
----------
TRADERS: GOLDMAN CUTS VODAFONE TO 'NEUTRAL' ('BUY')
----------
UBS CUTS VODAFONE PRICE TARGET TO 255 (275) PENCE -
LONDON (Alliance News) - Shares have opened marginally higher in London Thursday amid a flurry of UK corporate news and European economic statistics.
Electronics retailer Dixons Retail and mobile phone retailer Carphone Warehouse confirmed they will
May 14 (Reuters) - Pernix Therapeutics Holdings Inc said it would buy the U.S. marketing rights for a migraine treatment developed by GlaxoSmithKline Plc and Pozen Inc for an upfront payment of $250 million. Pernix's shares jumped as much as 42.5 percent in early trading on the Nasdaq.Read more
Last checked at